Thera-SAbDab

CUGRASTOMIG

>   Structural Summary
TherapeuticCugrastomig
Target 1LAG3/CD223
Heavy Chain 1QVQLQQWGAGLLKPSETLSLTCAVYGGSISDYYWNWIRQPPGKGLEWIGEINHRGTTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYDWFDPWGQGTLVTVSS
Light Chain 1EIVLTQSPATLSLSPGERATLSCRASQTISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTNLEIK
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 Structure7um3 [Fvs: HL, IM]
Target 2PDCD1/CD279/PD1
Heavy Chain 2EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS
Light Chain 2DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Cugrastomig.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 97.36%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
cugrastomig_Fv1 Q V Q L Q Q W G A G L L K P S E T L S L T C A V Y G G S I S D Y Y W N W I R Q P P G K G L E W I G E I N H R G T T N S N P S L K S R V T L S L D T S K N Q F S L K L R S V T A A D T A V Y Y C A F G Y S D Y E Y D W F D P W G Q G T L V T V S S
7um3 Q V Q L Q Q W G A G L L K P S E T L S L T C A V Y G G S F S D Y Y W N W I R Q P P G K G L E W I G E I N H N G N T N S N P S L K S R V T L S L D T S K N Q F S L K L R S V T A A D T A V Y Y C A F G Y S D Y E Y N W F D P W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
cugrastomig_Fv1 E I V L T Q S P A T L S L S P G E R A T L S C R A S Q T I S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S N W P I T F G Q G T N L E I K
7um3 E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S I S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S N W P L T F G Q G T N L E I K
>   Metadata
FormatBispecific Mixed mAb and scFv
IsotypeG1;na
Highest Clinical Trial (Aug '24)Phase-I
Estimated StatusActive
Recorded Developmental Technology
INN Year Proposed2024
INN Year RecommendedNone
Companies InvolvedAkeso Biopharma, Kangfang Huike (Shanghai) Biology Co
Conditions Approvedna
Conditions ActiveHER2-negative gastric cancer, Neoplasms, Refractory Hodgkin Lymphoma
Conditions Discontinuedna
NotesIvonescimab Fv2, Penpulimab, and Cugrastomig Fv2 have the same sequences.

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy